Efficacy and safety of tailored and dose‐dense adjuvant chemotherapy and trastuzumab for resected HER2‐positive breast cancer: Results from the phase 3 PANTHER trial. Cancer 2020; 126: 1175-1182.
Published: 17th November 2020
Authors: Papakonstantinou A, Matikas A, Bengtsson NO, Malmstrom P, Hedayati E, Steger G et al.
In this study that included 342 women, relapse-free survival was not significantly improved by the addition of trastuzumab: hazard ratio 0.68, 95 per cent confidence interval 0.37 to 1.27.Pubmed Link
You may also be interested in
Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised double-blind, phase 3 trial. Lancet 2020; 396: 1090-1100.
Authors: Mittendorf EA, Zhang H, Barrios CH, Saji S, Jung KH, Hegg R et al.
Phase III randomized trial of bisphosphonates as adjuvant therapy in breast cancer: S0307. J Natl Cancer Inst 2020; 112: 698-707.
Authors: Gralow JR, Barlow WE, Paterson AHG, M’iao JL, Lew DL, Stopeck AT et al.
Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-forward): 5-year efficacy and late normal tissue effects results from a multicenter, non-inferiority, randomised, phase 3 trial. Lancet 2020; 395: 1613-1626.
Authors: Brunt AM, Haviland JS, Wheatley DA, Sydenham MA, Alhasso A, Bloomfield DJ et al.
The effects of ganglioside-monosialic acid in taxane-induced peripheral neurotoxicity in patients with breast cancer: a randomized trial. J Natl Cancer Inst 2020; 112: 55–62
Authors: Su Y, Huang J, Wang S, Unger JM, Arias-Fuenzalida J, Shi Y et al.
Concurrent neoadjuvant chemotherapy and estrogen deprivation in patients with estrogen receptor–positive, human epidermal growth factor receptor 2–negative breast cancer (CBCSG‐036): A randomized, controlled, multicenter trial. Cancer 2019; 125: 2185-2193
Authors: Yu K-D, Wu S-Y, Liu G-Y, Wu J, Di G-H, Hu Z et al.
West German Study Plan B Trial: adjuvant four cycles of epirubicin and cyclophosphamide plus docetaxel versus six cycles of docetaxel and cyclophosphamide in HER2-negative early breast cancer. J Clin Oncol 2019; 37: 799-808
Authors: Nitz M, Gluz O, Clemens M, Malter W, Reimer T, Nuding B et al.
Authors: Schmid P, Cortes J, Pusztai L, McArthur H, Kummel S, Bergh J et al.
External beam accelerated partial breast irradiation versus whole breast irradiation after breast conserving surgery in women with ductal carcinoma in situ and node negative breast cancer (RAPID): a randomized controlled trial. Lancet 2019; 394: 2165-2172
Authors: Whelan TJ, Julian JA, Berrang TS, Kim D-H, Germain I, Nichol AM et al.
Long term results of accelerated partial breast irradiation after breast-conserving surgery for early-stage breast cancer: a randomized, phase 3, equivalence trial. Lancet 2019; 394: 2155-2164
Authors: Vicini FA, Cecchini RS, White JR, Arthur DW, Julian TB, Rabinovitch RA et al.
Use of anastrozole for breast cancer prevention (IBIS-II): long term results of a randomized controlled trial. Lancet 2020; 395: 117-122
Authors: Cuzik J, Sestak I, Forbes JF, Dowsett M, Cawthorn S, Mansel RE et al.
Randomized phase II study evaluating palbociclib in addition to letrozole as neoadjuvant therapy in estrogen receptor–positive early breast cancer: PALLET trial. J Clin Oncol 2019; 37: 178-189.
Authors: Johnston S, Puhalla S, Wheatley D, Ring A, Barry P, Holcombe C et al.
Adjuvant letrozole and tamoxifen alone or sequentially for postmenopausal women with hormone receptor–positive breast cancer: long-term follow-up of the BIG 1-98 Trial. J Clin Oncol 2019; 37: 105-114.
Authors: Ruhstaller T, Giobbie-Hurder A, Colleoni M, Jensen M-B, Ejlertson B, de Azambuja E et al.